Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

Chung Shan Medical University

Status: Completed

Conditions: Advanced Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04352335

CSMUH02-NLR

Details and patient eligibility

About

The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.

Full description

In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations.

Enrollment: 53 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Aged 20 years and older.
• Patients who have been given a diagnosis of lung cancer.
• Previously advanced lung cancer patients first treated with ICIs from Oct 1, 2015 to Oct 31, 2019.

Exclusion Criteria

• Patients who have no hematological laboratory data available at baseline (within 3 days prior to ICI treatment) and the 6th week (± 2 weeks) after ICI treatment initiation.

Trial design

53 participants in 2 patient groups

Cohort 1：ICI treatment with immunomodulator

Description:

Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.

Cohort 2：ICI treatment without immunomodulator

Description:

Lung cancer patients received immunological checkpoint inhibitors (ICIs).